SCHEMBL6662474

SCHEMBL6662474

CC#CCOc1ccc(Sc2cc(Cl)ccc2OC(C)=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.42
ADAM17 P78536 12/20 0.42
RAB9A P51151 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MMP9 P14780 7/20 0.38
MMP13 P45452 7/20 0.38
MMP1 P03956 5/20 0.38
MMP2 P08253 1/20 0.38
MMP14 P50281 1/20 0.38
TP53 P04637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PPARG P37231 1/20 0.35
PPARD Q03181 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656957 0.88 ADAM17 (0.47) PTGS2ADAM17RAB9ALMNAHTT
SCHEMBL6656710 0.87 PTGS2 (0.42) PTGS2ADAM17RAB9ALMNAHTT
SCHEMBL6655282 0.84 PTGS2 (0.57) PTGS2ADAM17
SCHEMBL6656394 0.82 ADAM17 (0.43) PTGS2ADAM17RAB9ALMNAHTT
SCHEMBL6658035 0.81 PTGS2 (0.39) PTGS2ADAM17RAB9ALMNAHTT
SCHEMBL6660771 0.80 MMP9 (0.44) ADAM17RAB9AALDH1A1MEN1KMT2A
SCHEMBL6655284 0.79 ADAM17 (0.51) ADAM17LMNAMMP9MMP13MMP1
SCHEMBL7413914 0.78 ADAM17 (0.40) PTGS2ADAM17RAB9ALMNAHTT
SCHEMBL6660831 0.78 ADAM17 (0.42) PTGS2ADAM17RAB9AALDH1A1MEN1
SCHEMBL7326200 0.78 ADAM17 (0.40) PTGS2ADAM17RAB9ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147080-B1 ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS WYETH CORP (US) 2004-07-21 EP disclosed
US-6340691-B1 TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION AMERICAN CYANAMID COMPANY 2002-01-22 US disclosed